The largest-ever clinical trial of a psychedelic drug will soon begin in Europe and North America to find a cure for depression.
The psychedelic drug is psilocybin – the active ingredient in magic mushrooms. The target is treatment-resistant depression. In the episode 27 of the After On Podcast, listeners are introduced to George Goldsmith and Katya Malievskaia. They are a married couple whose startup – Compass Pathways – will soon launch the largest triple-blind clinical trial ever of a psychedelic drug. The drug is psilocybin, an active ingredient derived from psychedelic mushrooms. And the condition is treatment-resistant depression. A condition that affects over a hundred million people worldwide. The term “treatment-resistant” implies, it lacks a cure.
While this may sound implausible, the individuals that have been drawn to this company’s work is quite remarkable. Their Board of Directors includes Thomas Lonngren, who spent ten years running Europe’s equivalent of the FDA (the European Medicines Agency). Also on their board is the former Chief Medical Officer of Bristol Meyers Squibb – one of the world’s largest pharmaceutical companies. In addition, they have raised roughly $20 million for their company from some extremely savvy investors.
This podcast showcases Katya and George’s their expansive knowledge in medical research. Their efforts are focused heavily on the drug approval process. Also, they have designed their trial in consultation with the top drug regulators of multiple countries.
Psychedelic drug as a potential cure for treatment-resistant depression
Katya and George express their strong sentiments against treatment-resistant depression. They describe how the illness has severely afflicted an individual very dear to them. Listeners will learn about Katya and George’s backgrounds, along with their motivations. As well as, the trial they are architecting and their company: Compass Pathways. The discussion the long clinical history certain psychedelics and other recreational drugs have had, and the major promise several of them are now showing against a diversity of afflictions.
Click here for some helpful resources on how to support individuals with depression or other mental health issues.